Punching Through: A Minimally Invasive Revolution in Bone-Anchored Hearing Devices?
"Discover how a refined surgical technique is improving patient satisfaction and stability in bone-anchored hearing solutions."
For individuals with hearing loss, bone-anchored hearing devices (BAHDs) offer a life-changing solution. Traditionally, the implantation process involved more invasive surgical techniques. However, a revolutionary method known as Minimally Invasive Ponto Surgery (MIPS) is changing the landscape, promising improved outcomes and enhanced patient experiences.
MIPS, first described in 2011 by Hultcrantz et al., utilizes a small 5mm dermal punch to create space for the Ponto abutment, minimizing soft tissue disruption. This approach contrasts sharply with traditional open surgery, which involves greater tissue removal. The key advantages of MIPS include shorter procedure times, better soft tissue preservation, and the potential for faster recovery.
Recognizing the potential benefits of MIPS, clinicians have been keen to adopt this technique. A recent study published in the Journal of Otolaryngology - Head & Neck Surgery explores the long-term stability and patient satisfaction associated with MIPS, providing valuable insights for those considering BAHDs.
Measured Benefits and Expanding Use
A 2022 report by J. King described the feasibility and safety of completing bone-anchored hearing implants with a minimally invasive punch technique in an office setting. A 2023 study reported extensive real-world data from 228 implants in 200 patients. Separately, a 2021 study found significant postoperative improvements in sound-field thresholds at all tested frequencies compared with unaided hearing. Evidence cited by HealthLink also suggests that bilateral devices may improve hearing outcomes over unilateral use in some individuals, although that evidence remains uncertain.
Established Surgery, Narrowing Eligibility
The minimally invasive percutaneous surgery (MIPS) technique has been described as simple to perform and associated with a low rate of intraoperative and postoperative complications. A 2022 comparison reported that MIPS involved a shorter surgical time than the linear-incision technique, with no significant difference in postoperative outcomes. Bone-anchored systems bypass the outer and middle ear rather than sending sound through the ear canal. Implantable devices are generally limited to individuals aged 5 years and older because younger children may lack sufficient skull thickness, bone quality, or maturity.
From Cardano to Modern Implants
The history of bone-conduction devices is commonly traced to the Italian physician Girolamo Cardano, who most likely developed an early device using a rod placed between a person's teeth and attached to a musical instrument. Bone-conduction hearing systems later became known as osseointegrated or bone-anchored devices. Johns Hopkins describes these systems as innovative technology approved by the Food and Drug Administration. Modern candidacy depends on factors including age, medical history, type of hearing loss, and personal circumstances.
MIPS: A Closer Look at Stability and Satisfaction
The study, conducted by Sardiwalla, Jufas, and Morris, followed 12 adult patients who underwent MIPS between 2016 and 2017. The researchers aimed to assess device stability and gather patient feedback on their surgical experience and overall satisfaction. This was achieved through prospective research clinics, implant site assessments, and patient interviews and surveys.
- Soft Tissue Status: Evaluated using the Inflammation, Pain, Skin Height (IPS) Scale.
- Patient Experiences: Assessed via the Surgical Satisfaction Questionnaire (SSQ-8) modified for MIPS.
- Device Stability: Monitored through follow-up examinations and patient reports.
A New Surgical Perspective
The reviewed article presents Minimally Invasive Ponto Surgery, or MIPS, as a new technique for placing bone-anchored hearing implants. Its focus is the surgical approach rather than a market forecast or a broad comparison with unrelated hearing technologies. The review frames MIPS as a new perspective on implantation. The available source material does not provide additional outcome figures or long-term comparative results.
Surgical Risks and Device Loss
Bone-anchored hearing aid placement requires a surgical procedure, can cost more than traditional hearing aids, and carries a risk of infection. A medical-policy summary also identifies skin problems, device failure, and the possible need for additional surgery as risks. That source reports implant loss estimates ranging from 6.1% to 19.4%, indicating variation across the evidence it reviewed. Bone-anchored systems are intended to combine osseointegration with bone-conduction auditory stimulation, but that design does not eliminate procedural or device-related complications.
Insufficient Comparative Evidence
The supplied comparative sources consist of discussion posts about BAHA versus cochlear implants and about bone-conduction devices for high sensorineural loss. Their snippets do not provide verifiable study results, outcome measures, or consistent comparisons. On the available material, no evidence-based conclusion can be drawn about which option provides better hearing outcomes. The comparison therefore remains unresolved rather than supporting a specific clinical ranking.
The Future of BAHDs: MIPS as the Preferred Approach
This study provides compelling evidence for the long-term stability and patient satisfaction associated with MIPS. The findings suggest that MIPS is not only a safe and effective technique but also offers significant advantages over traditional open surgery.
Reliable for Appropriate Candidates
A review of bone-anchored hearing systems describes them as reliable and predictable in appropriate patients with conductive or mixed hearing loss. This assessment is conditional on patient selection rather than a claim that the systems suit every type of hearing loss. It supports viewing bone-anchored technology as an established option for selected candidates. The source does not establish that minimally invasive surgery is superior for all patients.
Growth Estimates With Wide Variation
Market forecasts suggest continued expansion, but the supplied estimates differ substantially in scope and value. DelveInsight estimates a 6.21% compound annual growth rate for the global bone-anchored hearing systems market from 2024 to 2030. Fortune Business Insights values the global bone-conduction hearing devices market at USD 11.34 billion in 2026 and projects USD 20.83 billion by 2034, while other reports forecast the bone-anchored systems industry rising from USD 2,294.95 million in 2025 to USD 4,651.46 million by 2035 or the bone-anchored hearing aids market rising from USD 488 million in 2025 to USD 1.1 billion by 2035. These figures should not be treated as interchangeable because the sources describe different market categories and forecasts.
Outcomes Depend on Context
A 2024 study examined bone-conduction devices in patients with asymmetric hearing loss who wore the device on the worse-hearing side. Its focus included the situations in which the device was used, emphasizing that real-world benefit may depend on listening context. A separate policy summary reports within-subject improvements in hearing for partially implantable bone-anchored hearing aids. Together, these sources support evaluating performance in specific patients and situations rather than assuming uniform benefit.
From Clinical Benefit to Personal Meaning
One 2025 research-day case study described a 74-year-old female cadaver found to have a bone-anchored hearing aid during a medical-school gross-anatomy examination. This unusual case documents the presence of the device but does not provide information about the woman's hearing outcomes, satisfaction, or reasons for implantation. Another supplied source reports major improvements in hearing ability and speech understanding, including in noisy listening conditions, among study participants. The available material therefore points to potential functional benefit while offering limited detail about individual lived experience.
Clinicians are encouraged to carefully assess and evaluate new developments in patient treatment. As the study demonstrates, MIPS offers a refined approach to BAHD implantation, potentially leading to better patient outcomes and experiences. This is particularly relevant given the increasing demand for less invasive and more patient-centered surgical solutions.
With its proven stability, high patient satisfaction, and minimal complications, MIPS is poised to become the procedure of choice for percutaneous BAHD placement, marking a significant step forward in the treatment of hearing loss.